ArticleScientific reports2026
Comparative AI-optimized HPLC-DAD strategy for the simultaneous determination of ranolazine, amlodipine, and diltiazem with pharmacotherapeutic relevance and multi-trait sustainability assessment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A robust and reliable HPLC–DAD method was developed and validated for the simultaneous determination of ranolazine, diltiazem, and amlodipine, a drug combination relevant to the concurrent management of chronic angina and hypertension. Preliminary screening of chromatographic conditions was supported by an AI-assisted platform and subsequently refined through conventional experimental optimization. The proposed method was successfully applied to bulk materials and combined dosage forms. It was further extended to spiked rat plasma to verify its applicability for monitoring ranolazine in the presence of co-administered diltiazem and amlodipine. Chromatographic separation was achieved on a C18 column using an isocratic mobile phase consisting of buffer (pH 5), acetonitrile, and methanol (60:30:10, v/v) at a flow rate of 1.0 mL/min. The developed method provided efficient separation with satisfactory peak symmetry and resolution under optimized conditions. The AI-assisted predictions showed good agreement with experimentally optimized parameters, supporting their utility as a preliminary tool to guide method development. The method was validated in accordance with established guidelines, demonstrating satisfactory linearity, accuracy, precision, and selectivity within the studied concentration range. The analytical performance and environmental impact were evaluated and compared with previous methods using the Multi-Color Assessment tool, yielding an overall Whiteness Score of 64.8% overwhelming the other reported methods. In addition, the alignment of the AI-optimized method with sustainability principles was assessed using the Need, Quality, and Sustainability tool and compared with conventional optimization. The results demonstrate that the proposed method provides a reliable and environmentally considerate analytical approach for the simultaneous quantification of the studied drug combination in pharmaceutical formulations with demonstrated applicability in biological matrices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.